Single-photon Emission Computed Tomography (SPECT) to Predict Peritoneal Chemotherapy

This study has been completed.
Sponsor:
Information provided by:
Uppsala University
ClinicalTrials.gov Identifier:
NCT00997633
First received: October 16, 2009
Last updated: NA
Last verified: October 2009
History: No changes posted
  Purpose

SPECT was performed in 51 patients after cytoreductive surgery in combination with intraperitoneal chemotherapy. The detected volume was compared to the number of subsequent sequential postoperative intraperitoneal chemotherapy courses that could be performed without further surgical intervention. SPECT data was found to predict feasibility of sequential postoperative intraperitoneal chemotherapy.


Condition
Peritoneal Carcinomatosis

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: Single-photon Emission Computed Tomography for Prediction of Treatment Results in Sequential Intraperitoneal Chemotherapy at Peritoneal Carcinomatosis

Resource links provided by NLM:


Further study details as provided by Uppsala University:

Primary Outcome Measures:
  • Detected volume measured by SPECT compared to the number of subsequent sequential postoperative intraperitoneal chemotherapy courses [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The relationship between SPECT, feasibility of SPIC (intraperitoneal chemotherapy), and clinical variables [ Designated as safety issue: No ]

Enrollment: 51
Study Start Date: May 1991
Study Completion Date: August 2004
Primary Completion Date: August 2004 (Final data collection date for primary outcome measure)
Groups/Cohorts
Peritoneal carcinomatosis
Patients undergoing cytoreductive surgery and intraperitoneal chemotherapy treatment

  Eligibility

Ages Eligible for Study:   14 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients who had undergone cytoreductive surgery and intraperitoneal chemotherapy (SPIC) at the Dept of Surgical Sciences, Uppsala University Hospital in the time period between May 1991 and August 2004.

Criteria

Inclusion Criteria:

  • Cytoreductive surgery and intraperitoneal chemotherapy
  • Single-Photon Emission Computed Tomography (SPECT) before the second course of treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00997633

Locations
Sweden
Dept of Surgical Sciences, Section of Surgery
S-751 85 Uppsala, Sweden
Sponsors and Collaborators
Uppsala University
Investigators
Principal Investigator: Haile Mahteme, MD PhD Dept of Surgical Sciences, University Hospital, Uppsala, Sweden
  More Information

No publications provided

Responsible Party: Haile Mahteme, MD PhD, Dept of Surgical Sciences, Section of Surgery, Uppsala University, Sweden
ClinicalTrials.gov Identifier: NCT00997633     History of Changes
Other Study ID Numbers: SPECT IK1991:5
Study First Received: October 16, 2009
Last Updated: October 16, 2009
Health Authority: Sweden: Isotop Committee
Sweden: Regional Ethical Review Board

Keywords provided by Uppsala University:
Intraperitoneal volume
peritoneal carcinomatosis
cytoreductive surgery
SPECT
intraperitoneal chemotherapy

Additional relevant MeSH terms:
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on July 22, 2014